Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. The drug comes as an oral capsule. It’s usually taken once per day. Specifically, Ingrezza is used in ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...

April 30 (Reuters) - (This April 30 story has been corrected to say it was Neurocrine's movement disorder drug, not Huntington's disease drug, in the headline and to remove the reference to chorea in ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with ...

SAN DIEGO, Sept. 14, 2023 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ...

Valbenazine 40mg, 60mg, 80mg; oral granules in hard gel caps. Caps and Sprinkle caps: take with or without food. For Sprinkle caps: can open, sprinkle, and mix entire contents onto 1 tablespoonful of ...

(This April 30 story has been corrected to say it was Neurocrine's movement disorder drug, not Huntington's disease drug, in the headline and to remove the reference to chorea in paragraph 3) By ...

(Reuters) - The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease ...